

Freedom of Information Request	FOI 21-398	13 th October 2021
--------------------------------	------------	-------------------------------

1. How many patients have been treated with the following drugs (for any disease) in the past 6 months:

Aubagio (teriflunomide)	18
Avonex (interferon beta-1a)	7
Betaferon (interferon beta-1b)	2
Brabio (glatiramer acetate)	1
Copaxone (glatiramer acetate)	11
Extavia (beta interferon-1b)	0
Fampyra (fampridine)	4
Gilenya (fingolimod)	36
Lemtrada (alemtuzumab)	3
Mavenclad (cladribine)	3
Mayzent (siponimod)	0
Ocrevus (ocrelizumab)	83
Plegridy (peginterferon beta-1a)	7
Rebif (beta interferon-1a)	2
Tecfidera (dimethyl fumarate)	87
Tysabri (natalizumab)	43
Zeposia (ozanimod)	0

2. How many patients have been treated with the following drugs in the past 4 months:

Aimovig (erenumab) - any disease	
Ajovy (fremanezumab) - any disease	
Emgality (galcanezumab) - any disease	
Botulinum Toxin (i.e. Botox, Dysport, Xeomin) - for migraine ONLY	

Please refer to the spreadsheet attached

3. Does the trust either commission or fund Botulinum Toxin treatment and/or anti-CGRP monoclonal antibody treatments (Ajovy, Aimovig, Emgality) for migraine (Y/N)?

Yes

4. How many patients have been treated in the past 4 months for the following conditions:

Chronic migraine (15+ headache days per month)	No data
Episodic migraine (4-14 headache days per month)	No data
Relapsing remitting multiple sclerosis (RRMS)	No data
Primary progressive multiple sclerosis (PPMS)	No data
Secondary progressive multiple sclerosis (SPMS)	No data

The Health Board does not routinely collect this data.